Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Cervical cancer
- Focus Therapeutic Use
- 04 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2021 Trial design, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 15 Oct 2020 Status changed from not yet recruiting to recruiting.